Maca

Lepidium meyenii Walp. (Brassicaceae) is a low, biennial or short-lived perennial rosette native to the central Andean puna—especially the high plateau around Lake Junín in Peru, with a broader historical range into adjacent highland Bolivia. It is one of the few root crops that reliably sets a hypocotyl in the intense cold, UV, and wind above about 4,000 m. Leaves are ruffled, deeply lobed, and hug the ground. Flowers are tiny, four-petaled, typically white to off-white, in the mustard pattern. Fruit is a silicle. The “root” sold as maca is a fused hypocotyl and taproot: starch, sugar, and protein first, secondary metabolites second.

Hypocotyl color is a real agricultural fact and a marketing industry. Cream/yellow types dominate cultivation. Red and black phenotypes are less common and are sold with phenotype-specific claims (prostate folklore for red, spermatogenesis folklore for black). Composition does shift with color and with country of growth; that is not the same as a clinical indication printed on a pouch. Chinese-grown material has entered the trade; metabolomic work finds it chemically distinguishable from Peruvian tubers. “Maca” on a label is not a single chemotype.

Nomenclature is noisy. Walpers published L. meyenii in 1843. Gloria Chacón later named cultivated Peruvian maca Lepidium peruvianum. Most botanical databases and NCBI still treat the crop as L. meyenii; some analytical papers argue the names should not be collapsed. Products and papers use both. This page uses L. meyenii as the widely indexed name and flags L. peruvianum as the competing cultivated-name, not as a license to assume every bag is vouchered.

Glucosinolates (notably benzyl glucosinolate / glucotropaeolin and related aromatics) mark it as a mustard. Macamides and macaenes—benzylalkylamides and unsaturated fatty-acid derivatives—are often described as maca-characteristic; many macamides form or increase during traditional post-harvest drying, so fresh hypocotyl and gelatinized powder are not the same chemical object. Sterols, polysaccharides, and ordinary nutrients (carbohydrate, protein, minerals) make up most of the mass. Gelatinization (heat-and-pressure starch cooking) is a processing step to make dried root more digestible, not a potency spell.

Archaeology and ethnobotany place maca in the high Andes as a domesticated food long before capsules. The plant is adapted to a climate that kills most vegetables. Highland communities dried hypocotyls in the sun and frost, then boiled or ground them—cooking matters in the traditional safety story, as with other glucosinolate foods. Spanish colonial writers, including seventeenth-century accounts associated with Bernabé Cobo, described a highland root used as food. That is a crop history, not a clinical trial archive.

The late twentieth century invented the export maca. After a commercial “rediscovery” around the Junín plateau in the 1980s–90s, powder left Peru as a fertility and energy supplement. “Peruvian ginseng” stuck because ginseng already meant vitality in the global marketplace. The analogy is economic. Maca does not contain ginsenosides.

Laboratory and Peruvian clinical work clustered in the 2000s around Gustavo F. Gonzales and colleagues: sexual desire without a testosterone bump, semen parameters, hormone panels that mostly did not move in men. Those papers built the modern reputation. Systematic reviewers (Shin 2010 on sexual function; Lee 2011 on menopause) then said the quiet part: limited trials, limited size, limited quality, no firm conclusions. The hype and the evidence have not been the same size. Beharry and Heinrich’s 2018 ethnopharmacology review asked whether reproductive-health claims were justified and did not give marketing a free pass.

Color-coded branding is newer than the stew. Red, black, and yellow SKUs let a starch crop fragment into “for him” and “for her” products. Traditional Andean use was food first, with fertility among the medicinal stories told about a staple that kept people and herds going at altitude—not a PDE5 substitute shipped in pouches.

There is no single maca receptor. The plant is a mixed food: macronutrients, glucosinolates that can yield isothiocyanates, and lipid amides (macamides) that in vitro inhibit fatty acid amide hydrolase (FAAH) and sit near endocannabinoid talk. That lab story is not a measured human “anandamide boost.” Aqueous extracts used in some animal fertility work contain almost no macamides, which is a reminder that different extracts are different drugs in all but name.

In healthy men, maca has repeatedly failed to raise serum testosterone, LH, FSH, prolactin, or estradiol in the studies that measured them. Desire changes, when they appear, are therefore not a documented androgen spike. That distinction matters: maca is not a testosterone replacement, not an anabolic, and not a reason to skip a hypogonadism workup. A case report of immunoassay interference shows the other edge: maca can confuse some testosterone lab methods. Tell the laboratory if you take it.

In women, a few menopause and SSRI-sexual-dysfunction studies report symptom or sexual-function shifts, with inconsistent hormone findings. Some work reports FSH/LH wobble; other work finds psychological and sexual scores moving without estrogen or androgen content in the product explaining it. Brooks and colleagues (2008) put that in the title: benefits were not related to estrogen or androgen content. Do not treat maca as HRT.

Glucosinolates link maca to other brassicas. Very high intakes of raw crucifers can, in principle, stress iodine-thyroid economy. Traditional maca is cooked and dried. That is not a reason to eat unlimited raw powder if you have untreated hypothyroidism; it is a reason not to analogize it to kelp or to panic over a stew.

Food is the honest baseline. Dried hypocotyl, boiled or in flour (harina de maca), is highland calories and a mustard-sweet flavor. Gelatinized powders are easier to mix into drinks. That use does not require a sexual-function claim.

Sexual desire and mild erectile complaints are the main supplement pitch. Gonzales 2002 reported increased sexual desire in healthy men over weeks without a testosterone rise. Zenico 2009 reported subjective improvement in mild ED. Shin and colleagues’ 2010 systematic review of RCTs called the evidence limited: few trials, small samples, mixed quality, including a sports study that did not show an effect. A 2023 ED meta-analysis still had only two RCTs and could not underwrite a guideline. Maca is not sildenafil.

Semen quality is mixed. Early reports were optimistic. Lee’s 2016 review was cautious. A 2022 systematic review and meta-analysis did not show a significant sperm-concentration benefit versus placebo across RCTs. Some later small trials report concentration gains; they do not replace a urology or fertility clinic.

Menopause symptom trials (Lee 2011) found favorable Kupperman or Greene scores in a handful of RCTs and still concluded that numbers and quality were too thin for firm conclusions, with safety not established. Maca is not estrogen. It is not indicated hormone therapy.

SSRI-associated sexual dysfunction has two often-cited Dording papers: a 2008 dose-finding pilot (3 g looking better than 1.5 g in a tiny sample) and a 2015 placebo-controlled trial in women. Interesting, underpowered relative to the size of the marketing. Do not stop an antidepressant for a powder.

Energy, altitude, mood, and “adaptogen” claims sit on even thinner human evidence. Animal endurance and memory papers are not marathon protocols. Anti-aging skin claims have been reviewed as not effective. Sports studies are not a reason to skip sleep.

Traditional preparation is dried hypocotyl, then cooking. Raw dried powder is what many capsules contain; gelatinized powder is heat-processed for digestibility. Extracts are not interchangeable with food flour. Color (yellow/red/black) is a cultivar/phenotype label, not a USP monograph strength.

Trial doses in adults often fall around 1.5 to 3.5 g of dried root or equivalent per day for weeks, not months of undocumented megadosing. Products vary. There is no EMA herbal monograph equivalent to rosemary leaf. Follow a labeled food-like dose if you use it at all, and tell a clinician—especially before hormone labs.

Do not confuse maca with yohimbe, tribulus blends, or undeclared PDE5 analogues in “male enhancement” stacks. Sexual-enhancement products sold online are a documented adulteration neighborhood. A single-ingredient maca flour from a food supplier is a different object from a proprietary testosterone bottle.

Cooking traditional roots is the Andean pattern. Do not assume a raw mega-scoop is more authentic. Authenticity here is altitude agriculture, not powder extremism.

Food-like amounts are generally well tolerated. The common complaints in small trials are gastrointestinal (gas, gastritis, cramps), headache, insomnia, and moodiness. Subjective menstrual-cycle changes have been reported. One trial mentioned flu-like symptoms and vomiting without a clean causal call.

LiverTox rates maca as an unlikely cause of clinically apparent liver injury (likelihood E) based on the absence of a convincing signal in trials and registries. A 2017 case of jaundice after a large volume of “maca medicinal liquor” is a reminder that mixed alcoholic herbal drinks are not the dried hypocotyl.

MSKCC notes possible interference with testosterone immunoassays and cautions people with hormone-sensitive cancers to talk with their oncology team—because of mixed estrogenic signals in vitro and unclear human hormone effects, not because maca is proven HRT.

Thyroid: treat maca as a cooked brassica, not as kelp. If you have iodine deficiency or unstable thyroid disease, large raw-powder habits belong in a clinician conversation.

Pregnancy and breastfeeding: concentrated supplements are poorly studied. MSKCC advises discussing use; food-level traditional intake in Andean diets is a different exposure than a 3 g capsule. Do not self-prescribe maca for fertility while pregnant.

Hormone-sensitive cancers (breast, endometrium, prostate, and related settings): disclose maca. In vitro estrogenic activity and rare lab-test chaos are reasons for oncology input, not for a social-media protocol.

Do not use maca as a substitute for evaluation of infertility, hypogonadism, major depression, or cardiovascular erectile dysfunction. Those are diagnoses.

Allergy to mustard-family plants is a theoretical stop. Unknown “male enhancement” blends that list maca among twenty ingredients are a stop for a different reason: adulteration risk.

Documented human drug–drug interactions are sparse. A rat study of a related Lepidium with losartan is not a maca monograph. Still tell a pharmacist if you take antihypertensives, thyroid hormone, tamoxifen or other endocrine therapy, or antidepressants—because the sexual-function trials sit in those clinics, not because CYP3A4 collapse is maca’s reputation (it is not St. John’s wort).

Lab interaction: maca may interfere with some testosterone immunoassays. If a result looks biologically implausible, mention the powder before anyone starts androgens or withholds them.

Do not stack maca with yohimbe or unregulated ED drugs to “potentiate.” That is how people discover adulterants.

Iodine/thyroid medication: keep brassica intake consistent and cooked if you are titrating levothyroxine; do not binge raw maca powder as a new variable.